Hospitals, physicians, private payors and governments are considered the most important targets for pharmacoeconomic data. Patients are comparatively unimportant - they lack power in reimbursement and prescribing decisions. With the rise of advocacy groups and their increasing lobbying power, patients may warrant more attention in the US, although it will be difficult to adapt highly complex information to make it understandable by a broad audience.